

1 **SUPPLEMENTARY APPENDIX.**

2 A betacoronavirus multiplex microsphere immunoassay detects early SARS-CoV-2  
 3 seroconversion and antibody cross reactions

4 Eric D. Laing<sup>1\*</sup>, Spencer L. Sterling<sup>1,3</sup>, Stephanie A. Richard<sup>2,3</sup>, Nusrat J. Epsi<sup>2,3</sup>, Shreshta Phogat<sup>1,3</sup>,  
 5 Emily C. Samuels<sup>1,3</sup>, Lianying Yan<sup>1,3</sup>, Nicole Moreno<sup>2,3</sup>, Christian Coles<sup>2,3</sup>, Matthew Drew<sup>4</sup>, Jennifer  
 6 Mehalko<sup>4</sup>, Caroline English<sup>2,3</sup>, Scott Merritt<sup>2,3,5</sup>, Katrin Mende<sup>2,3,5</sup>, Kevin K. Chung<sup>6</sup>, G. Travis Clifton<sup>5</sup>,  
 7 Vincent J. Munster<sup>7</sup>, Emmie de Wit<sup>7</sup>, David Tribble<sup>2</sup>, Brian K. Agan<sup>2,3</sup>, Dominic Esposito<sup>4</sup>, Charlotte  
 8 Lanteri<sup>2</sup>, Edward Mitre<sup>1</sup>, Timothy H. Burgess<sup>2</sup>, and Christopher C. Broder<sup>1\*</sup>

9

10 **Table S1. MMIA SARS-CoV-2 RBD performance**

|   | SARS-CoV-2 PCR Status/Archival Sera |          |          |       |
|---|-------------------------------------|----------|----------|-------|
|   |                                     | Positive | Negative | Total |
| SARS-CoV-2<br>MMIA IgG<br>Antibody Test | Positive                            | 135      | 0        | 135   |
|   | Negative                            | 20       | 114      | 134   |
|   | Total                               | 155      | 114      | 263   |
|   | Sensitivity                         | 87.1%    |          |       |
|   | Specificity                         | 100%     |          |       |

11


12 **Table S2. IgG and IgM seropositivity within 28 days post-symptom onset (dspso)**

| dspso   | IgG+          | IgG+/IgM+     |
|---------|---------------|---------------|
| 7 – 14  | 80.0% (12/15) | 73.3% (11/15) |
| 15 – 28 | 100% (31/31)  | 93.5% (29/31) |

13

14

15



16

17 **Figure S1. SARS-CoV-2 IgG detection in experimentally challenged NHP serum samples.**

18 A sigmoidal curve was used to fit the MEAN±SEM of two independent experiments performed in  
19 technical triplicates. MFI, median fluorescence intensities.

20

21

22

23

24

25

26

27

28

29

30

31


32

33


34

35

36 **A.**



**B.**



37

38 **Figure S1. Establishment of 99.7% probability threshold MFI cutoffs for SARS-CoV-2**

39 **positive antibodies.** Convalescent serum samples (n= 43) from HCoV PCR-positive subjects

40 were tested in the  $\beta$ -CoV MMIA to determine **(A)** IgG antibody and **(B)** IgM antibody reactivity to

41 SARS-CoV-2 spike protein and RBD with a pre-2019 sera bank. Data represent the MEAN of

42 three independent experiments performed in technical duplicates.

43

44


45

46

47

48

49



50

51 **Figure S3. Receiver operating characteristic curve analysis of SARS-CoV-2 spike protein**

52 **IgG antibody reactivity in a  $\beta$ -CoV MMIA.** PCR-confirmed SARS-CoV-2 positive and negative

53 serum samples (n= 422) were tested with  $\beta$ -CoV MMIA and 100% was achieved at threshold

54 cutoff of 4854 MFI.

55

56

57

58

59


60

61

62

63


64  
65  
66



67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78

**Figure S4. Receiver operating characteristic curve analysis of SARS-CoV-2 spike protein IgM antibody reactivity in a  $\beta$ -CoV MMIA.** PCR-confirmed SARS-CoV-2 positive and negative serum samples (n= 105) were tested with  $\beta$ -CoV MMIA and 100% specificity was achieved at threshold cutoff of 1446 MFI.

79  
80  
81  
82



83

84 **Figure S5. Positive and negative results are reproducible over independent MMIA tests.**  
85 Selected positive(s) and negative serum samples were tested across independent experiments.  
86 CV, coefficient of variation, percentages are indicated on the graphs for each sample. A solid  
87 line indicates the threshold cutoff for positive IgG.

88  
89  
90  
91  
92  
93  
94